PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
1.24%
ROE exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.44%. Joel Greenblatt would check if high returns reflect a sustainable advantage.
1.09%
ROA of 1.09% while Drug Manufacturers - Specialty & Generic median is zero. Peter Lynch would see if minimal profitability can widen over time.
1.00%
ROCE of 1.00% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if moderate profitability can widen vs. peers.
86.44%
Gross margin exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 53.87%. Joel Greenblatt would see if cost leadership or brand drives the difference.
18.01%
Margin of 18.01% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if moderate profitability can be leveraged further.
20.46%
Net margin exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.04%. Joel Greenblatt would see if this advantage is sustainable across cycles.